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The goal of this pilot study was to compare longitudinal changes in fatigue, depressive 
symptoms, sleep, and activity in women (n = 10) undergoing intraperitoneal (IP) versus 
intravenous (IV) chemotherapy for ovarian cancer. Fatigue and depressive symptoms 
were assessed via self –report and sleep and activity via wrist actigraphy in the week 
before and the week after the first infusion. Both groups demonstrated increases in 
fatigue and depressive symptoms, declines in sleep, reduced daytime activity, and 
decreased rhythmicity of sleep/activity patterns (p<.05). Effect sizes for within-group 
comparisons tended to be higher in the IP group (ds = -.15 to -8.03) than the IV group (ds 
= .12 to 1.40).  Between-group comparisons revealed that IP patients demonstrated 
trends towards more severe symptoms post-chemotherapy in nearly all outcomes (p<.10).  
These results suggest that IP patients experience large increases in fatigue, depressive 
symptoms, and alterations in sleep and activity relative to IV patients. 
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El estudio comparó cambios longitudinales en fatiga, síntomas depresivos, sueño y 
actividad en mujeres con cáncer de ovario (n=10) en tratamiento con quimioterapia 
intraperitoneal (IP) versus intravenosa (IV). Se evaluó la fatiga y los síntomas depresivos 
(autoreferidos), y el sueño y la actividad (actigrafia) la semana antes y la posterior a la 
primera infusión. Ambos grupos refirieron mayor fatiga y síntomas depresivos, 
disminución del sueño, de la actividad diaria y de los patrones de ritmicidad 
sueño/actividad (p<.05). Las comparaciones entre el grupo IP (ds = -.15 to -8.03) y el 
grupo IV (ds = .12 to 1.40), y las comparaciones entre-grupos revelaron que los síntomas 
eran más graves en los pacientes IP (p<.10). Los datos obtenidos sugieren que los 
pacientes IP experimentan mayor incremento en fatiga, síntomas depresivos y 
alteraciones del sueño y la actividad en comparación con los pacientes IV. 
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There has been significant interest recently 
in the use of intraperitoneal (IP) chemotherapy for 
treatment of ovarian cancer.  This interest is 
attributable to several large randomized clinical trials 
(Alberts et al., 1996; Armstrong et al., 
2006; Markman et al., 2001) and meta-analyses (Elit 
et al., 2007; Jaaback & Johnson, 2006) suggesting a 
survival advantage of 8-16 months of IP over 
intravenous (IV) cisplatin-based regimens for patients 
with optimally-debulked Stage III ovarian cancer (Elit 
et al., 2007). On the basis of this evidence, the 
National Cancer Institute issued a clinical 
announcement in 2006 recommending that IP 
chemotherapy be considered for these 
patients (Trimble & Christian, 2008).  Nevertheless, 
there is ongoing debate regarding the use of IP 
chemotherapy (Armstrong & Brady, 2006; Gore, Du 
Bois & Vergote, 2006) due in part to concerns about 
toxicity and tolerability (Armstrong & Brady, 2006; 
Lesnock et al., 2010).  
 
To date, only one study has examined quality 
of life in patients receiving IP treatment. Data from 
the Gynecology Oncology Group GOG-172 
trial (Armstrong et al., 2006; Von Gruenigen et al., 
2011;  Wenzel, Huang, Armstrong, Walker & Cella, 
2007) compared overall quality of life as well as 
neurotoxicity, abdominal discomfort, and an index of 
ovarian cancer symptoms in 415 patients receiving 
IP and IV regimens. After adjusting for age, 
performance status, and baseline scores, IP patients 
reported significantly poorer overall quality of life, 
worse physical and functional well-being, and greater 
ovarian cancer symptoms at cycle 4 and 3-6 weeks 
post-treatment; worse abdominal discomfort at cycle 
4; and greater neurotoxicity at 3-6 weeks and 12 
months post-treatment (Armstrong et al., 2006; 
Wenzel et al., 2007).  These differences are notable 
and likely underestimate the effects of IP treatment 
on quality of life, as 40% of IP patients received two 
or fewer cycles of IP chemotherapy due to treatment 
toxicities (Armstrong et al., 2006).  
 
While the GOG-172 trial represents an 
important first step in describing quality of life in 
patients treated with IP chemotherapy, additional 
research is needed to provide a more complete 
clinical picture of symptoms experienced by IP 
patients.  This research is important because it can 
help patients make informed treatment decisions; 
both the Gynecology Oncology Group (Alberts et al., 
2006), and the American College of Obstetricians 
and Gynecologists (2008) have concluded that the 
choice to receive IP treatment should ultimately be 
made by informed patients.  The aim of this pilot 
study was to examine changes in fatigue, depressive 
symptoms, sleep, and activity in ovarian cancer 
patients undergoing IP versus IV chemotherapy.  
These four symptoms were selected because they 
tend to be particularly disruptive and troubling to 
ovarian cancer patients (Anderson & Hacker, 2008; 
Havrilesky et al., 2009).  Participants were assessed 
the week before and the week after the first 
treatment because symptoms may be most acute 
during this period.  It was hypothesized that IP 
patients would show greater increases in symptoms 
(i.e., fatigue, depression, disturbances in sleep and 
activity) over time and more severe post-treatment 
symptoms than IV patients. 
 
 
 
Table 1. Actigraphic Measurement of Sleep and Activity 
 
Construct Variable 
Direction 
indicating better 
functioning 
Sleep 
quality 
Mean duration of nighttime rest 
periods 
-- 
 Mean percentage of nighttime 
rest periods spent sleeping 
Higher 
 Mean number of times the 
participant woke up during the 
nighttime rest period 
Lower 
 Mean time until sleep onset Lower 
 Mean time awake after sleep 
onset (i.e., WASO) 
Lower 
 Mean percent of daytime non-
rest periods spent sleeping 
Lower 
Activity Mean activity per minute during 
nighttime rest periods 
Lower 
 Mean activity per minute during 
daytime non-rest periods 
Higher 
Sleep/acti
vity 
patterns 
Mesor (i.e., overall mean 
activity level for 24-hour period) 
Higher 
 Mean dichotomy index (i.e., 
activity during daytime non-rest 
periods divided by activity 
during nighttime rest periods) 
Higher 
 
2.1. Participant Selection and Recruitment 
 
Following Institutional Review Board 
approval, participants were recruited between 
January, 2007 and April, 2008.  Patients were eligible 
to participate if they: 1) were at least 18 years of age; 
2) were diagnosed with ovarian cancer; 3) were 
scheduled to undergo IP or IV chemotherapy at 
Moffitt Cancer Center (Tampa, Florida; United 
States) had not previously undergone chemotherapy 
or radiotherapy in the three months prior to study 
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recruitment; 5) had no documented or observable 
psychiatric or neurological conditions that would 
interfere with study participation; 6) were capable of 
reading and speaking English; and 7) were able to 
provide informed consent.  
 
2.2. Procedures 
 
Participants were recruited and informed 
consent obtained during a regularly scheduled 
outpatient appointment with their medical oncologist 
at Moffitt Cancer Center. Participants began 
sleep/activity monitoring with wrist actigraphy a mean 
of 6.7 days (range 4-8) before the first treatment and 
wore actigraphs continuously a mean of 6.1 (range 4-
7) after the first treatment.  Participants also 
completed self-report measures of fatigue and 
depressive symptoms at their first treatment and one 
week later. 
 
2.3. Measures 
 
Demographic and clinical variables.  Age, 
race, ethnicity, marital status, annual household 
income, and education were assessed in all 
participants through self-report.  Data regarding time 
since diagnosis, disease stage, disease recurrence, 
and current chemotherapy regimen were collected 
via medical chart review. 
 
Fatigue.  The Fatigue Symptom Inventory 
(FSI) (Hann et al., 1998) is a 14-item measure that 
assesses the frequency and severity of fatigue and 
its perceived disruptiveness in the past week.  
Analyses were conducted using ratings of most 
fatigue in the past week (0 = not at all fatigued, 10 = 
as fatigued as I could be).  Previous research has 
demonstrated the reliability and validity of the FSI in 
cancer patients (Hann et al., 1998). 
  
Depressive symptoms.  The 20-item Center 
for Epidemiological Studies of Depression Scale 
(CES-D) (Radloff, 1977) scale identifies current 
symptoms of depression in the past week.  Scores 
range from 0 to 60, with higher scores indicating 
greater depressive symptoms.  Previous research 
has demonstrated the reliability and validity of the 
CES-D in individuals with cancer (Hann, Winter & 
Jacobsen, 1999). 
  
Sleep, activity, and sleep/activity patterns.  
Sleep, activity, and sleep/activity patterns were 
assessed via actigraphic monitoring using the 
Actiwatch®-Score (MiniMitter, Bend, OR).  
Actigraphy is a reliable and valid way of objectively 
measuring sleep and physical activity (Patterson et 
al., 1993; Webster, Kripke, Messin, Mullaney & 
Wyborney, 1982) which demonstrates expected 
relationships with clinically-relevant outcomes (e.g., 
quality of life) in cancer patients (Mormont & 
Waterhouse, 2002).  In accordance with the 
recommendations of Berger et al. (2008), sleep, 
activity, and sleep/activity patterns were calculated 
using actigraphy data in combination with patients’ 
daily reports of bedtime and rising time using 
Actiware 5 software.  Actigraphy variables are 
defined in Table 1.  
 
 
 
Table 2. Sociodemographic and Clinical Characteristics of the 
Sample. 
 
 IV (n=5) IP (n=5) Statistic 
Age – M(SD) 58.17 (15.79) 
46.61 
(8.58) W = 35 
Ethnicity (% non-
Hispanic) 100% 80% χ
2 = 1.11 
Race (% Caucasian) 80% 80% χ2 = 0 
Marital status (% 
married) 80% 100% χ
2 = 1.11 
Education (% college 
grad) 40% 40% χ
2 = .09 
Annual household 
income (% ≥ $40k) 33% 66% χ
2 = .66 
Months since initial 
diagnosis 
7.32 
(15.36) 4.68 (6.21) W = 22 
Disease stage   χ2 = 3.14 
 Stage I 20% 0 (0%)  
 Stage II 20% 0 (0%)  
 Stage III 60% 80%  
 Stage IV 0% 20%  
Recurrent disease  
(% yes) 10% 0% χ
2 = 1.11 
Chemotherapy regimen   χ
2 = 
10.00** 
 Carboplatin/ paclitaxel 100% 0%  
 Cisplatin/ paclitaxel 0% 100%  
Note:   Wilcoxon-Mann-Whitney and Fisher exact tests were used.  
Not all participants reported education or household income data. 
**p<.01 
Wilcoxon-Mann-Whitney and Fisher exact 
tests were used to compare sociodemographic and 
clinical characteristics between IP and IV 
groups (see Table 2). Within- and between-group 
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comparisons in symptoms were conducted using 
Wilcoxon signed rank tests and Wilcoxon-Mann-
Whitney tests, respectively.  All analyses were 
conducted using SAS 9.2. To examine the clinical 
significance of group differences in symptom change 
and symptoms at Time 2, we also calculated effect 
sizes by subtracting the mean at the first assessment 
from the mean of the second assessment, then 
dividing by the pooled standard deviation. For the 
sake of comparison, Cohen defined small, medium, 
and large effect sizes as .2, .5, and .8, 
respectively (Cohen, 1988).  An effect size of .5 or 
higher is considered clinically significant (Frost et al., 
2007). 
 
 
Table 3 - Means, Standard Deviations, and Within- and Between-Group Effect Sizes of Fatigue, Depression, and Sleep/Activity Patterns 
 
 IV (n=5) IP (n=5) Time 2 IV vs. IP 
 Time 1 Time 2 d Time 1 Time 2 D  d  
Fatigue (FSI) 3.20 (3.27) 7.20 (4.21)  1.22 3.00 (3.08) 7.60 (2.51)  1.49    .12 
Depressive symptoms (CES-
D) 11.00 (9.97) 18.40 (8.14)    .74 8.0 (6.35) 25.46 (12.33)  2.66
†    .69 
Duration of nighttime rest 
periods (min) 484.51 (71.18) 572.56 (100.63)  1.24 512.67 (31.82) 565.49 (69.83)  1.66
†   -.08 
Activity during nighttime rest 
periods (activity counts) 38.33 (16.02) 45.65 (22.80)    .46 36.87 (3.01) 46.00 (1.69)  3.03
†    .03 
Percent sleep during 
nighttime rest periods 81.65 (3.24) 77.62 (7.45)  1.24 77.76 (.97) 75.16 (2.62)  2.68
†   -.49 
Wake bouts during nighttime 
rest periods (number) 24.64 (11.18) 28.11 (10.37)    .31 33.65 (4.54) 30.62 (8.02)   .67    .27 
Sleep onset during nighttime 
rest periods (minutes) 22.93 (14.36) 24.62 (9.51)    .12 16.48 (10.76) 14.82 (7.47)   .15 -1.15 
Wake after sleep onset 
during nighttime rest periods 
(minutes) 
59.50 (14.07) 95.89 (42.97)  2.59 84.19 (21.16) 109.13 (28.92)  1.17    .37 
Activity during daytime 
(activity counts) 239.52 (85.96) 218.12 (68.77)   .25 
368.99 
(108.48) 181.79 (24.64)  1.73
†   -.78 
Percent sleep during daytime 17.34 (7.87) 25.09 (12.17)    .98 8.18 (2.64) 29.39 (8.74)  8.03†    .41 
Mesor 204.50 (68.34) 146.10 (47.90)   .85† 266.49 (93.66) 141.79 (15.09)  1.33†   -.14 
Dichotomy index (I/O) .16 (.05) .23 (.14)  1.40 .11 (.03) .26 (.05)  5.00†    .32 
Note: No comparisons were statistically significant at p<.05. 
† p<.10 using Wilcoxon Signed Rank Tests 
 
 
As shown in Table 3, both IV and IP patients 
demonstrated increases in fatigue and depressive 
symptoms as well as declines in almost all indices of 
sleep. IP and IV patients also demonstrated 
alterations over time in activity, including decreased 
activity during daytime periods and greater activity 
during nighttime rest periods, as well as worse 
rhythmicity of sleep and activity.  Effect sizes for 
within-group comparisons tended to be higher in the 
IP group (ds = .15 to 8.03) than the IV group (ds = 
.12 to 1.40), with the exception of wake after sleep 
onset (WASO).  Between-group comparisons at Time 
2 revealed that the IP group demonstrated more 
severe symptoms in all indices measured with the 
exception of duration of rest periods and sleep onset.  
Among symptoms more severe for IP patients, 
activity during nighttime rest periods (d = .78) and 
depressive symptoms (d = .69) showed the greatest 
differences. No within- or between-group 
comparisons reached statistical significance (i.e., p < 
.05), as would be expected given the small sample 
size . However, trends (ps < .10) were observed for 
within-group changes in mesor (i.e., average activity 
values over a 24 hour period) in IV patients and for 
the majority of within-group changes in IP patients. 
Regarding clinical significance, both IV and IP 
patients at Time 2 reported mean FSI and CES-D 
scores above clinical threshold of 7 for severe fatigue 
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on the FSI (Berger et al., 2009) and 16 for clinically 
significant depressive symptomatology on the CES-
D (Andresen, Malmgrem, Carter & Patrick, 1994).  
Moreover, IP and IV patients reported increases in 
nighttime rest by 53 and 88 minutes and increases in 
wake after sleep onset by 25 and 36 minutes, 
respectively.  
 
 
 
The present pilot study compared within- and 
between-group differences in fatigue, depressive 
symptoms, sleep, and activity in women receiving IP 
versus IV chemotherapy for ovarian cancer.  Both IP 
and IV patients displayed increases in fatigue and 
depressive symptoms and declines in sleep in the 
week after their first chemotherapy infusion as 
compared to before.  These declines have been well-
documented in IV patients (Roscoe et al., 2002), but 
to our knowledge this is the first study to examine 
these symptoms in IP patients.  The magnitude of 
these changes was generally large, with effect sizes 
of .8 standard deviations or above in seven of the 
twelve outcomes measured in IV patients and ten of 
twelve outcomes in IP patients.  Particularly notable 
in IP patients were changes of several standard 
deviations in fatigue, depressive symptoms, activity 
during rest, activity during non-rest periods, sleep 
during non-rest periods, and disrupted sleep/activity 
patterns.  These data help to document the 
subjective symptoms and objective behavioral 
changes that women experience as they struggle to 
cope with IP as compared to IV treatment.   
 
Strengths of the current study include a 
longitudinal design as well as assessment with 
actigraphy and well-validated measures of 
depressive symptoms and fatigue.  Nevertheless, the 
study is not without its limitations.  First, patients 
were not randomized to receive IP versus IV 
chemotherapy, so attribution of group differences in 
symptoms to treatment must be considered with 
caution.  Patients showed group differences in age, 
stage, and annual household income.  Although non-
significant, these differences may have affected 
between-group comparisons.  Second, the study 
lacked long-term follow-up assessments to document 
how symptoms changed as treatments progressed 
and then ceased.  Third, the chemotherapy regimens 
were different between groups, with the IV group 
receiving carboplatin/paclitaxel and the IP group 
receiving cisplatin/paclitaxel, which may have 
contributed to group differences.  Fourth, the sample 
size was small.  The small sample size may result in 
less reliable estimates of group means and standard 
deviations and necessitated less-powerful non-
parametric statistical tests, which may explain a lack 
of statistically significant differences despite large 
effect sizes.  The sample size in the current study 
was a function of the small number of patients 
receiving IP chemotherapy at Moffitt Cancer Center 
as well as an a priori decision to recruit a comparable 
number of IP and IV patients.   
 
The small number of IP patients reflects 
several possible barriers to widespread adoption of 
IP treatment, despite the fact that it is currently the 
standard of care for some ovarian cancer patients 
(Trimble & Christian, 2008).  First, relatively small 
numbers of patients meet criteria for its use.  
Second, there is significant debate in the field of 
gynecologic oncology regarding whether the survival 
benefits of IP treatment outweigh the risks of long-
term toxicity.  Finally, if given the choice, patients 
themselves may be reluctant to undergo IP treatment 
in light of greater toxicity and increased treatment 
burden (i.e., inpatient versus outpatient 
administration after the first infusion). 
 
5.  
 
Debate regarding the use of IP 
chemotherapy for ovarian cancer will only be 
resolved through additional research. To this end, the 
current pilot study provides an initial longitudinal 
comparison of four common and distressing 
symptoms: changes in fatigue, depressive 
symptoms, sleep, and activity in patients receiving 
platinum-based IP or IV chemotherapy.  Future 
research should build upon the pilot data presented 
here to conduct larger, well-powered follow-up 
studies of these symptoms.  Research of this kind 
has the potential to greatly enhance informed 
decision-making among women considering IP 
versus IV chemotherapy for ovarian cancer. 
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